Clinical Trials Logo

Clinical Trial Summary

This study investigates the add-on effect of oral minocycline in subjects treated with daily injection of Copaxone. Copaxone and minocycline are thought to have differential modes of actions that may complement each other in treating MS symptoms.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00203112
Study type Interventional
Source Teva Pharmaceutical Industries
Contact
Status Completed
Phase Phase 2
Start date June 2004
Completion date July 2006

See also
  Status Clinical Trial Phase
Recruiting NCT04857489 - Deficient T Regulatory Cell (Treg) Function in Patients With Relapsing Remitting Multiple Sclerosis
Active, not recruiting NCT05084638 - Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls. Phase 4
Recruiting NCT05705986 - Immunoregulatory Effect of Microparticle Delivered STING Agonist in the Control of Experimental Autoimmune Encephalomyelitis (EAE) and Multiple Sclerosis (MS)
Completed NCT00203099 - Safety and Efficacy Study of Copaxone Administered in Combination With N-Acetylcysteine Phase 2
Terminated NCT02038049 - A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis Phase 2